WilmerHale Advises Tetraphase Pharmaceuticals in Merger with AcelRx Pharmaceuticals 

WilmerHale Advises Tetraphase Pharmaceuticals in Merger with AcelRx Pharmaceuticals 

Client News

Related Solutions

Lawyers with deep and broad experience counseling clients in every industry on the design, implementation, and interpretation of executive compensation arrangements and on general compensation and benefits issues.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
WilmerHale lawyers have decades of experience advising public and private companies in all aspects of mergers and acquisitions.
A deep and diverse practice focused on maximizing tax efficiencies and minimizing tax risks for clients nationally and internationally.
We leverage technical knowledge, business acumen and legal experience to structure, prepare and negotiate innovative and effective technology-related agreements.
On March 16, 2020, Tetraphase Pharmaceuticals, Inc. (Nasdaq: TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVA to treat serious and life-threatening infections, and AcelRx Pharmaceuticals (Nasdaq: ACRX) announced that they have entered into a definitive merger agreement pursuant to which AcelRx would acquire Tetraphase in a stock for stock transaction. Concurrently with signing the merger agreement, Tetraphase and AcelRx also entered into a co-promotion agreement to market and promote XERAVA™ for the treatment of complicated intra-abdominal infections and DSUVIA® for the treatment of acute pain in medically supervised settings.

WilmerHale is representing Tetraphase in the deal, with a team led by partners Stuart Falber, Hal Leibowitz and Chris Barnstable-Brown, which also included senior associate Tim Kulis and associate Meghan Fay on corporate and M&A matters, and partners Kim Wethly, Julie Hogan Rodgers, Scott Kilgore and Steve Barrett and associate Ben Kelsey on tax, executive compensation, employment and benefits and intellectual property matters. Associate Gerard Fischetti also worked on corporate and M&A matters. 

Read the full press release.
 

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel